Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)
- Conditions
- Hepatitis C
- Interventions
- Drug: PegIFN/RBVDrug: BI 201335Drug: Placebo
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2015-09-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 656
- Registration Number
- NCT01343888
- Locations
- 🇧🇪
1220.30.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1220.30.3203 Boehringer Ingelheim Investigational Site, Liège, Belgium
🇧🇪1220.30.3205 Boehringer Ingelheim Investigational Site, Gent, Belgium
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: placeboDrug: BI1356 low doseDrug: BI1356 high dose
- First Posted Date
- 2011-04-27
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01342484
- Locations
- 🇲🇽
1218.56.52008 Boehringer Ingelheim Investigational Site, Chihuahua, Mexico
🇨🇦1218.56.11001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada
🇫🇷1218.56.33006 Boehringer Ingelheim Investigational Site, Rouen, France
Drug Drug Interaction of BI 201335 and Tenofovir
- Conditions
- HIV Infections
- Interventions
- Drug: tenofovir/BI 201335
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT01340196
- Locations
- 🇺🇸
1220.50.0001 Boehringer Ingelheim Investigational Site, Buffalo, New York, United States
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
- First Posted Date
- 2011-04-22
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 285
- Registration Number
- NCT01340209
- Locations
- 🇯🇵
205.464.81006 Boehringer Ingelheim Investigational Site, Edogawa-ku, Tokyo, Japan
🇯🇵205.464.81002 Boehringer Ingelheim Investigational Site, Hitachinaka, Ibaraki, Japan
🇯🇵205.464.81023 Boehringer Ingelheim Investigational Site, Kamogawa, Chiba, Japan
A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer
- Conditions
- Neoplasms
- Interventions
- Drug: BI 853520
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT01335269
- Locations
- 🇳🇱
1300.2.31002 Boehringer Ingelheim Investigational Site, Utrecht, Netherlands
🇨🇦1300.2.1001 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇳🇱1300.2.31003 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 515
- Registration Number
- NCT01335464
- Locations
- 🇧🇪
1199.32.32004 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1199.32.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇨🇳1199.32.86005 Boehringer Ingelheim Investigational Site, Changsha, China
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II
- First Posted Date
- 2011-04-14
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 551
- Registration Number
- NCT01335477
- Locations
- 🇺🇸
1199.34.10080 Boehringer Ingelheim Investigational Site, Stamford, Connecticut, United States
🇺🇸1199.34.10070 Boehringer Ingelheim Investigational Site, Portland, Oregon, United States
🇺🇸1199.34.10074 Boehringer Ingelheim Investigational Site, Durham, North Carolina, United States
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
- Conditions
- Ovarian Neoplasms
- Interventions
- Drug: BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*minDrug: BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*minDrug: BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2014-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT01329549
- Locations
- 🇯🇵
1199.117.003 Boehringer Ingelheim Investigational Site, Akashi, Hyogo, Japan
🇯🇵1199.117.002 Boehringer Ingelheim Investigational Site, Chuo-ku,Tokyo, Japan
🇯🇵1199.117.001 Boehringer Ingelheim Investigational Site, Hidaka, Saitama, Japan
A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients
- Conditions
- Hepatitis C
- Interventions
- Drug: BI 201335Drug: PegIFN/RBV
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 119
- Registration Number
- NCT01330316
- Locations
- 🇨🇦
1220.48.1007 Boehringer Ingelheim Investigational Site, Victoria, British Columbia, Canada
🇺🇸1220.48.0087 Boehringer Ingelheim Investigational Site, Baton Rouge, Louisiana, United States
🇺🇸1220.48.0027 Boehringer Ingelheim Investigational Site, Framingham, Massachusetts, United States
Drug-drug Interaction of Empagliflozin (BI 10773) and Microgynon
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01328184
- Locations
- 🇩🇪
1245.41.1 Boehringer Ingelheim Investigational Site, Biberach, Germany